Why the study?
CVD is the leading cause of death in early-stage breast cancer, and adherence to CVD risk factor medications is poor, but the association between nonadherence and cardiovascular events was unknown.
Does nonadherence to cardiovascular risk factor medications increase the incidence of cardiac events in early-stage breast cancer survivors?
Population
15,576 patients with stages I to III breast cancer taking at least 1 CVD-RF medication
Comparison
Nonadherence vs adherence to CVD-RF medications after initial breast cancer treatment
Design
Retrospective database cohort study (SEER-Medicare)
Authors
Loading...
Nonadherence may raise CV event risk in BC survivors; hypothesis-generating and requires prospective confirmation before practice change.
Does nonadherence to cardiovascular risk factor medications increase the incidence of cardiac events in early-stage breast cancer survivors?
Nonadherence to cardiovascular risk factor medications after breast cancer treatment is associated with a significantly increased risk of subsequent cardiac events, highlighting the importance of managing non-cancer comorbidities in survivors.
Hershman et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: